Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 bimekizumab study in moderate to severe hidradenitis suppurativa
2019-002551-42Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Bimekizumab with Placebo (2 arms). Primary endpoint: HiSCR50 at Week 16. Started Jan 2020; status: completed.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2019-002551-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002551-42.